Preimplantation genetic diagnosis market

Preimplantation genetic diagnosis is used to test aneuploidy in the cases of low prognosis in patients opting for in vitro fertilization. It is also instrumental in detection of hereditary single gene disorders, X linked diseases and recently, also for diagnosis of late onset diseases.

Statistics:

The global preimplantation genetic diagnosis market is estimated to account for US$ 53.5 Mn in terms of value in 2020 and is expected to reach US$ 81.6 Mn by the end of 2027.

Global Preimplantation Genetic Diagnosis Market: Drivers

Increasing incidences of genetic diseases is expected to propel growth of the global preimplantation genetic diagnosis market over the forecast period. For instance, according to the study, ‘Estimating Nationwide Prevalence of Live Births with Down Syndrome and Their Medical Expenditures in Korea’, published in Journal of Korean Medical Science in August 2019, the prevalence of live births with Down’s syndrome was 5.03 per 10,000 births between 2007 and 2016.

Moreover, increasing number of fertility centers is also expected to aid in growth of the global preimplantation genetic diagnosis market. For instance, in November 2018, Oregon Reproductive Medicine, a fertility center, started its new clinic in Tigard, Oregon called ORM South.

Statistics:

Chromosomal Abnormalities held dominant position in the global preimplantation genetic diagnosis market in 2019, accounting for 20.1% share in terms of value, followed by X-linked diseases and Aneuploidy, respectively.

Figure 1. Global Preimplantation Genetic Diagnosis Market Share (%), by Value, by Type, 2019

Global Preimplantation Genetic Diagnosis Market: Restraints

Non-availability of embryos for transfer is expected to hinder growth of the global preimplantation genetic diagnosis market. In almost one third of couples opting for preimplantation genetic diagnosis cycles, the result is that there is absence of normal transferrable embryos. This could be owing to the reason that sometimes women may show poor response to the given ovarian stimulation and as a result lesser eggs are produces. In other cases, despite there is an availability of a fair quantity of embryos, their chromosomal value is found to be consistently abnormal.

Moreover, couples who fail in previous IVF of preimplantation genetic diagnosis cycles have very low chances of future success. Such disadvantages further holdback growth of the global preimplantation genetic diagnosis market.

Global Preimplantation Genetic Diagnosis Market: Opportunities 

Application of preimplantation genetic diagnosis in the field of oncology is expected to offer lucrative growth opportunities for players in the global preimplantation genetic diagnosis market. Preimplantation genetic diagnosis has the potential of reducing the chances of conceiving a cancer affected pregnancy. It can help in determination of the gender of the embryo and further only the genetically fit embryos will be implanted and a healthy pregnancy can thus be conceived.

Moreover, further development in DNA technology will improve accuracy in preimplantation genetic diagnosis, thereby aiding in growth of the market.

The global preimplantation genetic diagnosis market was valued at US$ 50.3 Mn in 2019 and is forecast to reach a value of US$ 81.6 Mn by 2027 at a CAGR of 6.2% between 2020 and 2027.

Figure 2. Global Preimplantation Genetic Diagnosis Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

Market Trends/Key Takeaways

Major players in the global preimplantation genetic diagnosis market are focused on launching new products to expand their product portfolio. For instance, in December 2018, Agilent Technologies Inc. introduced OnePGT, a genome-wide, next-generation sequencing (NGS) solution for preimplantation genetic testing.        

Moreover, increasing network of fertility centers is expected to aid in growth of the global preimplantation genetic diagnosis market. For instance, in October 2018, Prelude Fertility partnered with NYU Langone Health to establish NYU Langone Fertility Center (Fertility Center).

Global Preimplantation Genetic Diagnosis Market: Competitive Landscape

Major players operating in the global preimplantation genetic diagnosis include, Amgen, Quest Diagnostics, Genentech Inc., Vertex, PerkinElmer, Inc., F. Hoffman-La-Roche Ltd, Thermo Fisher Scientific, Inc., Laboratory Corporation of America Holdings, Abbott Laboratories, Illumina, Inc., Natera Inc., CooperGenomics Inc., Reproductive Genetics Institute, Inc., Genea Ltd., Invitae Corporation, and CombiMatrix Corporation.

Global Preimplantation Genetic Diagnosis Market: Key Developments

Major players in the global preimplantation genetic diagnosis market are focused on adopting partnership and collaboration strategies to enhance their market share. For instance, in July 2020, Thermo Fisher Scientific partnered with First Genetics JCS, a manufacturer of diagnostic equipment and IVD kits intended to advance molecular genetic technologies into clinical practice, for commercialization of next-generation sequencing (NGS)–based diagnostics in Russia.